AstraZena will resume phase III trial in matter of time after adverse event solve.

Sell on technical rebound, as vaccine development still on track to release next month

sold back all supermax at 6.96-7.00

If indeed jaks-wb 47sen can compensated with new jaks-wb 1.5 for every 1, at least no so bad after jaks ex-right adjust down to 28sen

It’s illogical for exiting Jaks wb to get another free Jaks wb warrant at all

It is free to additional Jaks wb only if Jaks declare bonus share or share split, but now, Jaks is call for right share, and only those subscribe can entitle new free Jaks Wc. Jaks wb can covert to Jaks by paid exercise price 64sen to entitle right and free new Jaks wc.

As Jaks right share will lead to adjustment market price after ex-right to 28sen, current Jaks-wb is big loser.

However, Jaks wb will get offer to subscribe additional Jaks wb, 1.5 new Jaks wb for every 1 exiting Jaks wb at lower cost later ( should be less than Jaks right share 12sen) as the circular indicate no free entitlement to additional Jaks wb.

Dk

The Proposed Rights Issue with Warrants may give rise to the adjustment to the exercise price and/ or additional number of LTIP Options and Warrants B pursuant to the relevant by-laws and deed poll.
Any necessary adjustments to the exercise price and additional number of LTIP Options and Warrants B to be issued arising from the Proposed Rights Issue with Warrants can only be finalised after the Entitlement Date in accordance with the provisions as contained in the relevant by-laws and deed poll. A notice will be despatched to the respective holders of the LTIP Options and Warrants B in the event of any such adjustments.

There is no clause indicate that additional Jaks wb up to 151 million will be issue ‘free’ to exiting Jaks-wb holder. Previously, Jaks -wb need to subscribe at 25sen. I presume it still need to pay to get additional Jaks-wb, but with lower cost and exercise price also at lower strike price if compared to current 64sen.

The danger of current Jaks-wb is that only Jaks is entitle to right and warrant. As the right is 3 for 1, issue at 12sen, Jaks current share price assume retain at 78.5sen will be adjusted to about 28sen and hold 3 Jaks -OR which is sellable to market once listing in bursa for a week.

Imagining, current Jaks-Wb trading at 47sen, entitle nothing will be trade higher than Jaks price ?

Can warrant price trade higher than underlying price !?

Jaks-wb at 47sen will total lose out after Jaks ex trade at below 30sen. It is warning sign to Jaks-wb as they entitle nil to right and new warrant, only their exercise price get adjusted. Get rid of Jaks WB now before too late, the cash proceed can use to buyback Jaks -OR later to direct entitle Jaks right at 12 sen + free warrant. Take caution stand to Jaks wb to avoid unnecessary loss later.

Yesterday many was too excited on Jaks near completion first unit power plant that may generate million of revenue, without notice that Jaks have change its right and warrant ratio again to even higher dilutive than expected and slash even lower right subscription at 12sen.

1. First proposed 2 right + 1 warrant for every 4 share, issue at 40sen !

2. Second revise proposed 8 right + 4 warrant for every 5 share, issue at 22.5sen !!

3. Latest circular proposed 3 right for every 1 share, together with 1 warrant for every 2 right subscribe at 12sen !!!

The EGM will conduct on 24 sept, announcement entitlement in early Oct and listing in mid Nov. it is advisable to avoid totally current Jaks-wb as it have nil right to entitle, only lower exercise price.

As there will be huge 3 x higher volume, almost 2 billion right for right Jaks-OR will be list in bursa, it is better to buy these Jaks-OR directly to straight subscribe and entitle free warrant instead of current Jaks which likely under pressure later.

Investor only need to buy Jaks-OR based on market price once listed next month + paid right price 12sen = list as new Jaks share + new free Jaks-Wc.

bought all supermax at 6.10

Alternatively, await for listing of right for right issue, Jaks-OR to be listing for a week which allow to direct subcribe to right share and entitle warrant. As the listing Jaks-OR is huge, 3 x higher volume, It could have arbitrarily gap to be capitalize.

Please take note, only Jaks holder are entitled to to subscribe right + new free warrant.

No entitlement is given to Jaks-Wb at all, the only impact on Jaks wb is adjustment to its exercise price from 64sen to price to be determine later. Take caution

Jsks-WB at 51sen should take extra caution as they are no entitle to new right share + new free warrant.

Although Jaks-WB exercise price will adjust downward from current 64sen, but even adjust lower to 10 sen or even 1 sen also cannot compete with new upcoming Jaks-WC which is issue at free + exercise price 28sen.

In the nutshell, Bonus = split, the effect is same.

The only different is bonus share capitalize on capital reserve in balance sheet, while split is outright divided share volume. The dilution to earning is same in accord to share base enlarge.

After kitchen sinking, AWC forward earning will be brighter with back of long term concession steady earning.

The exercise price for new upcoming free warrant C is at 28sen.

Current Jaks-Wb exercise price is at 64sen, it will however adjust down the exercise price to be determine later.

Jaks right proposed keep changing ever from

1. First proposed 2 right + 1 warrant for every 4 share, issue at 40sen !

2. Second revise proposed 8 right + 4 warrant for every 5 share, issue at 22.5sen !!

3. Latest circular proposed 3 right for every 1 share, together with 1 warrant for every 2 right subscribe at 12sen !!!

Time to take off glove before too late.

https://klse.i3investor.com/servlets/ptres/56929.jsp

Time to take off glove before too late.

https://klse.i3investor.com/servlets/ptres/56929.jsp

To Glove lover, glove now is downtrend stock due to speedy vaccine to market sooner, Pfizer vaccine answer next month, follow by China vaccine year end, take caution ya

https://www.marketwatch.com/story/biontech-pfizer-expect-clinical-answer-on-coronavirus-vaccine-in-late-october-2020-09-09

https://www.scmp.com/news/world/americas/article/3100930/brazil-could-launch-chinese-coronavirus-vaccine-year-says

To Glove lover, glove now is downtrend stock due to speedy vaccine to market sooner, take caution ya

https://www.marketwatch.com/story/biontech-pfizer-expect-clinical-answer-on-coronavirus-vaccine-in-late-october-2020-09-09

https://www.scmp.com/news/world/americas/article/3100930/brazil-could-launch-chinese-coronavirus-vaccine-year-says

Post removed.Why?

Brazil could launch Chinese coronavirus vaccine this year, says governor, citing ‘extremely positive’ results

Widespread vaccination campaign using Sinovac’s CoronaVac could begin as early as December
Vaccine produced immune response in 98 per cent of recipients over 60, with no adverse side-effects reported so far, said Sao Paulo’s governor


https://www.scmp.com/news/world/americas/article/3100930/brazil-could-launch-chinese-coronavirus-vaccine-year-says

Iwcity, IWH, Ekovest, all are interlink sister company, with past record to take over Iwcity as RM 1.50.

1) Fresh Fruit Bunches - 114,525 metric tonnes

2) Crude Palm Oil - 20,974 metric tonnes

3) Palm Kernel - 4,954 metric tonnes

4) Logs - 22,341 cubic metres

More than 150 covid vaccines are in development across the world—and hopes are high to bring one to market in record time to ease the global crisis.

Among them, 8 vaccine already enter into final stage of phase III trials. Half of them, 4 vaccines that are from China.

Some glove lover may wan to highlight that one vaccine stop from AstraZaneca, but it doesn't stop other vaccine advance to finalization last phase III trial to get one effective vaccine.

In nutshell, globally, human only need one effective vaccine for protection instead of 8 or more ineffective vaccine.

The good thing about China final vaccine trial is that it conduct outside China, spread across different race and region globally, in middle east, South American, Brazil, Asia: Indonesia, Pakistan. These globally establish data will solidify, verify and endorse by WHO and to be follow by global healthcare including FDA

(of course if Trump refuse to adopt China vaccine due to political agenda, other country will still rush to get vaccine which is approval by WHO)

https://www.globaltimes.cn/content/1200192.shtml

More than 150 covid vaccines are in development across the world—and hopes are high to bring one to market in record time to ease the global crisis.

Among them, 8 vaccine already enter into final stage of phase III trials. Half of them, 4 vaccines that are from China.

Some glove lover may wan to highlight that one vaccine stop from AstraZaneca, but it doesn't stop other vaccine advance to finalization last phase III trial to get one effective vaccine.

In nutshell, globally, human only need one effective vaccine for protection instead of 8 or more ineffective vaccine.

The good thing about China final vaccine trial is that it conduct outside China, spread across different race and region globally, in middle east, South American, Brazil, Asia: Indonesia, Pakistan. These globally establish data will solidify, verify and endorse by WHO and to be follow by global healthcare including FDA

(of course if Trump refuse to adopt China vaccine due to political agenda, other country will still rush to get vaccine which is approval by WHO)

https://www.globaltimes.cn/content/1200192.shtml

More than 150 covid vaccines are in development across the world—and hopes are high to bring one to market in record time to ease the global crisis.

Among them, 8 vaccine already enter into final stage of phase III trials. Half of them, 4 vaccines that are from China.

Some glove lover may wan to highlight that one vaccine stop from AstraZaneca, but it doesn't stop other vaccine advance to finalization last phase III trial to get one effective vaccine.

In nutshell, globally, human only need one effective vaccine for protection instead of 8 or more ineffective vaccine.

The good thing about China final vaccine trial is that it conduct outside China, spread across different race and region globally, in middle east, North American, Brazil, Asia: Indonesia, Pakistan. These globally establish data will solidify, verify and endorse by WHO and to be follow by global healthcare including FDA

(of course if Trump refuse to adopt China vaccine due to political agenda, other country will still rush to get vaccine which is approval by WHO)

https://www.globaltimes.cn/content/1200192.shtml

Immediate resistance level at 53sen, once broken, sky is limit for mutlibillion orderbook

Bear in mind, four of the world's eight vaccines that are in the final third phase of trials are from China. One vaccine stop from AstraZaneca halt doesn't stop other continue to finalization to get effective vaccine.

For three groups of participants who respectively took two shots of low, medium and high-dose CoronaVac, over 90% of them experienced significant increase in antibody levels, while the levels were slightly lower than those seen in younger subjects but in line with expectation

FDA only require 50% efficacy for vaccine approval, China vaccine being tested in many country have >90% efficacy rate ------- approval from WHO and FDA is matter of time

In nutshell, globally, human only need one effective vaccine for protection instead of 8 or more ineffective vaccine.

Bear in mind, four of the world's eight vaccines that are in the final third phase of trials are from China. One vaccine stop from AstraZaneca halt doesn't stop other continue to finalization to get effective vaccine.

For three groups of participants who respectively took two shots of low, medium and high-dose CoronaVac, over 90% of them experienced significant increase in antibody levels, while the levels were slightly lower than those seen in younger subjects but in line with expectation

FDA only require 50% efficacy for vaccine approval, China vaccine being tested in many country have >90% efficacy rate ------- approval from WHO and FDA is matter of time

In nutshell, globally, human only need one effective vaccine for protection instead of 8 or more ineffective vaccine.

FDA only require 50% efficacy for vaccine approval, China vaccine being tested in many country have >90% efficacy rate ------- approval from WHO and FDA is matter of time

FDA only require 50% efficacy for vaccine approval, China vaccine being tested in many country have >90% efficacy rate ------- approval from WHO and FDA is matter of time

Four of the world's eight vaccines that are in the third phase of trials are from China. For three groups of participants who respectively took two shots of low, medium and high-dose CoronaVac, over 90% of them experienced significant increase in antibody levels, while the levels were slightly lower than those seen in younger subjects but in line with expectation, Liu said in a statement.

https://www.thestar.com.my/aseanplus/aseanplus-news/2020/09/08/who-working-with-china-on-requirements-for-covid-19-vaccine-approval

Four of the world's eight vaccines that are in the third phase of trials are from China. For three groups of participants who respectively took two shots of low, medium and high-dose CoronaVac, over 90% of them experienced significant increase in antibody levels, while the levels were slightly lower than those seen in younger subjects but in line with expectation, Liu said in a statement.

https://www.thestar.com.my/aseanplus/aseanplus-news/2020/09/08/who-working-with-china-on-requirements-for-covid-19-vaccine-approval

WHO: Working with China on requirements for Covid-19 vaccine approval

Four of the world's eight vaccines that are in the third phase of trials are from China.

https://www.thestar.com.my/aseanplus/aseanplus-news/2020/09/08/who-working-with-china-on-requirements-for-covid-19-vaccine-approval

WHO: Working with China on requirements for Covid-19 vaccine approval

Four of the world's eight vaccines that are in the third phase of trials are from China.

https://www.thestar.com.my/aseanplus/aseanplus-news/2020/09/08/who-working-with-china-on-requirements-for-covid-19-vaccine-approval

Key word 'billions in order book'

We are in the midst of a global build-out of vaccine development and manufacturing capacity of unprecedented scale—essentially a global Manhattan Project for vaccines. While undoubtedly good for humanity and science, the likely consequence will be a glut of production capacity and rapid commoditization of vaccine candidate technologies.

China have 3 vaccine candidate in final phase 3 trial, Sinovac, Sinopharm, and CNBG vaccine. Around 50,000 people, across a number of countries, are participating in final phase 3 clinical trials. In US, Moderna has enrolled more than 21,400 patients in its vaccine’s Phase 3 trial, but the team of Pfizer (PFE) and BioNTech (BNTX) have enrolled more than 25,000 in theirs, while AstraZeneca (AZN) has active trials around the globe.

Manufacturing capacity for the many vaccine projects will be vast, as governments have contracted with Moderna and its rivals. The U.S. has already signed up for 800 million doses with 6 different vaccine developers, with options for an additional 1.8 billion.

We are in the midst of a global build-out of vaccine development and manufacturing capacity of unprecedented scale—essentially a global Manhattan Project for vaccines. While undoubtedly good for humanity and science, the likely consequence will be a glut of production capacity and rapid commoditization of vaccine candidate technologies.

China have 3 vaccine candidate in final phase 3 trial, Sinovac, Sinopharm, and CNBG vaccine. Around 50,000 people, across a number of countries, are participating in final phase 3 clinical trials. In US, Moderna has enrolled more than 21,400 patients in its vaccine’s Phase 3 trial, but the team of Pfizer (PFE) and BioNTech (BNTX) have enrolled more than 25,000 in theirs, while AstraZeneca (AZN) has active trials around the globe.

Manufacturing capacity for the many vaccine projects will be vast, as governments have contracted with Moderna and its rivals. The U.S. has already signed up for 800 million doses with 6 different vaccine developers, with options for an additional 1.8 billion.

IWH takes cognizance of Ekovest as being one of its long-term trusted business partners that has the necessary skills and technical know-how to undertake largescale infrastructure developments. The Bandar Malaysia Project is a prime national economic project, in which Ekovest’s direct participation and investment in IWH-CREC will potentially generate billions in order book sales arising from future infrastructure and development of Bandar Malaysia, which has an estimated gross development value (GDV) of approximately RM140 billion.

IWH takes cognizance of Ekovest as being one of its long-term trusted business partners that has the necessary skills and technical know-how to undertake largescale infrastructure developments. The Bandar Malaysia Project is a prime national economic project, in which Ekovest’s direct participation and investment in IWH-CREC will potentially generate billions in order book sales arising from future infrastructure and development of Bandar Malaysia, which has an estimated gross development value (GDV) of approximately RM140 billion.

Malaysia back to 3 digit new cases, its worrisome for labor intensive glove maker in Malaysia. If case worsen, or if any one of foreign glove worker at risk getting virus, the plant have to force shutdown for quarantine.

Malaysia back to 3 digit new cases, its worrisome for labor intensive glove maker in Malaysia. If case worsen, or if any one of foreign glove worker at risk getting virus, the plant have to force shutdown for quarantine.

prime mature tree ----> fruit contain highest oil -----> process by own mill, reap full value chain

AGM coming, date of dividend 15sen entitlement will be announce soon

If CPO above RM 3000, jtiasa share price will trade above 90sen based on last year record

Malton + WCT = ?

Malton + WCT = ?

Anything surplus above production cost RM 1600-1800 are PURE profit

CPO still above RM 2900